I N T R O D U C T I O N
Deregulated mineral metabolism is a hallmark of end-stage renal disease (ESRD) [1] . Specifically, hyperparathyroidism (HPT) with hyperplastic or hypertrophic parathyroid glands occurs commonly in patients with ESRD (30-50%) [2, 3] . Eventually HPT contributes to progressively disturbed calcium-phosphate homeostasis and eventually to autonomous parathyroid hormone (PTH) overproduction and hypercalcaemia Clinical HPT-related manifestations vary from somatic symptoms such as fatigue and abdominal pain, to psychological symptoms such as forgetfulness, mood swings and concentration difficulties [4] . Furthermore, HPT has been associated with versatile detrimental effects on health status, especially with respect to bone disorders, cardiovascular disease, increased risk of mortality and even reduced quality V C The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Nephrol Dial Transplant (2017) 32: 1902-1908 doi: 10.1093/ndt/gfx044 Advance Access publication 10 April 2017 of life (QoL) [5] [6] [7] [8] . The QoL of ESRD patients is often already decreased, due to both the symptoms of ESRD itself and the burden of dialysis treatment [9] .
In the management of HPT, different treatment modalities are available. According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, patients with ESRD-related HPT should initially receive medical therapy with vitamin D analogues and phosphate binders. Upon failure of initial therapy, prescription of the calcimimetic agent cinacalcet is recommended [10] . Cinacalcet increases the sensitivity of the calcium-sensing receptor (CaSR) located within the parathyroid glands, aiming to reduce excretion of PTH and balance calcium-phosphate homeostasis [11] . KDIGO guidelines recommend parathyroidectomy (PTx) only in patients with severe HPT (>800 pg/mL) who are refractory to medical therapy. Since its introduction in 2004, cinacalcet has gained a dominant role in the treatment algorithm of ESRD-related HPT and PTx is less often performed [12] . However, emerging data suggest that the reticent position of surgery in the treatment algorithm of HPT might be questionable. In a previous study, we showed that PTx is a very safe and effective treatment [13] . Furthermore, Narayan et al. [14] showed that PTx is more cost effective than cinacalcet after 7.25 months of treatment. Since no randomized controlled trial (RCT) comparing PTx with cinacalcet has been performed so far, the optimal treatment of ESRD-related HPT remains unclear.
In order to provide a patient-tailored approach to HPT, it is of paramount importance to also assess the effect of these interventions on QoL, in line with the increasing interest in patientreported outcome measures (PROMs) [15] . It is known that PTx improves QoL in patients with primary HPT; however, whether there is an additional positive effect of PTx or cinacalcet in patients with concurrent ESRD remains uncertain [16] . Therefore, we performed a systematic review of studies measuring QoL in patients with HPT who received cinacalcet or underwent (sub)total PTx.
M A T E R I A L S A N D M E T H O D S

Search strategy
To identify relevant articles, a systematic literature search was conducted using PubMed and EMBASE. The following search terms were used to identify articles on the effect of PTx on QoL: 'parathyroidectomy', 'secondary hyperparathyroidism', 'tertiary hyperparathyroidism', 'quality of life', 'SF-36' and 'symptomatology'. Next, we used the following search terms to identify articles describing the effect of cinacalcet on QoL: 'secondary hyperparathyroidism', 'tertiary hyperparathyroidism', 'cinacalcet hydrochloride', 'quality of life', 'SF-36' and 'symptomatology'. Additionally, we searched for abstracts and unpublished studies on the websites of the US Food and Drug Administration (FDA), European Medicines Agency (EMA), American Society of Nephrology (ASN) and European Dialysis and Transplant Association (EDTA). The search protocol has not been published or submitted to an ethical committee.
Article selection and data extraction
Only original research papers written in English and published between 1980 and 2015 were included for further analysis. The abstracts were screened by two independent reviewers (R.R.D., W.Y.vdP.) and all articles complying with the following criteria were selected: (i) studies assessing QoL using any kind of health questionnaire-both general and diseasespecific questionnaires were included-and (ii) QoL was assessed both at baseline and during follow-up after PTx or initiation of cinacalcet in HPT patients. In case of disagreement, a third reviewer was consulted (T.M.vG. or S.K.). After this selection process, all full-text articles were studied and a cross-reference check was performed. Our online search yielded 277 articles; 2 articles were additionally found by cross-referencing. Eventually, five publications on PTx met the inclusion criteria and were included in this review. Three relevant manuscripts on the effect of cinacalcet on QoL were selected (Figure 1 ). Corresponding authors were asked to provide additional data if the article did not contain the required information. Secondary endpoints of our analyses were biochemical measurements including PTH, calcium and phosphate levels before and after intervention. No additional studies or abstracts where found on the websites of the FDA, EMA, ASN or EDTA.
Quality assessment
All eligible articles were independently scored regarding their quality by three reviewers blinded to each other's results (W.Y.vdP., R.R.D. and S.K.). In case of disagreement, the article was discussed and a definitive score was calculated based on consensus. Case series were assessed by means of the 18-criteria checklist by the Delphi panel [17] . This validated checklist includes the quality of the study objective, population, intervention and co-intervention, outcome measures and statistical analysis. A maximum of 18 points could be awarded. A score of 14-18 points was considered high quality and 9-13 was considered fair quality. For case-control and cohort studies, the Newcastle-Ottawa scale was used [18] . The scale consists of three domains addressing the aspects of methodology, including selection, comparability and outcome (cohort studies) or exposure (case-control studies) for which stars could be allotted. A total of 9 stars could be awarded. A score of 7-9 was considered high quality and 4-6 was considered fair quality. Articles reporting an RCT were assessed using the CONsolidated Standards of Reporting Trials (CONSORT) 2010 statement [19] . Also, the risk of publication bias was assessed using a funnel plot.
QoL and symptoms measurement tools
The Medical Outcomes Study Short-Form Health Survey (SF-36) is a commonly applied questionnaire of 36 simple questions on eight health domains. Each dimension can be transformed into a 0-100 scale, where a higher score represents better selfperceived well-being and QoL. These eight domains are divided into two summery scores: the physical component summary score (PCS) and the mental component summary score (MCS). For both the PCS and the MCS, a score of 50 represents the mean of the US population (SD 10). In haemodialysis patients, the reported mean PCS ranges from 31.6 to 49.8 and MCS varies from 46.0 to 50.2 [20] [21] [22] . A change in PCS or MCS scores of a minimum of 2 points is thought to be clinically meaningful [23] .
The European QoL 5-Dimensions (EQ-5D) assessment is another classification instrument. It encompasses five domains: mobility, self-care, usual activities, pain or discomfort and anxiety or depression each with three response levels [24] .
Pasieka and Parsons [4] developed a disease-specific outcome tool for HPT. The parathyroidectomy assessment of symptoms (PAS) is a questionnaire that contains all HPTrelated symptoms and was initially designed for primary HPT. This 13-item questionnaire has been validated for secondary and tertiary HPT and is correlated to the SF-36 questionnaire [25] . A visual analogue scale (VAS) ranging from 1 to 100 is used to assess the degree of severity per symptom. The 13 included symptoms are bone pain, fatigue, mood swings, feeling 'blue' or depressed, abdominal pain, feeling weak, feeling irritable, joint pain, forgetfulness, difficulty getting out of a chair or car, headaches, itchy skin and being thirsty, with a maximum PAS score of 1300.
Statistics
Mean QoL scores were extracted from the selected manuscripts. Weighted means were calculated as follows: (number of patients Â mean score difference)/total number of patients.
R E S U L T S
Description and quality of the included studies A description of the included studies is shown in Table 1 . Of the five included studies on PTx, four provided SF-36 scores, three of which reported the summary scores. Two articles also assessed QoL by means of the PAS score and one article used a general VAS system. There were no multicentre studies and follow-up ranged from 3 to 12 months. All studies stated a complete objective and/or hypothesis and outcome measures were clearly described in all studies. In 80% of the studies, patients had been recruited consecutively. All studies reported the length of follow-up, but only one of the five studies mentioned the number of participants lost to follow-up. All authors drew conclusions fully supported by their results. We considered three articles to be of high quality and two of fair quality.
Three studies reporting the effect of cinacalcet on QoL were included. One was based on the EVOLVE (EValuation Of Cinacalcet Hydrochloride Therapy to Lower CardioVascular Events) trial, a multicentre RCT comparing cinacalcet with placebo [32] . All manuscripts stated clear hypotheses and endpoints were fully described.
The risk of publication bias could not be tested since <10 studies were included in this analysis.
Effect of PTx on QoL
All studies reported significant improvement in QoL after PTx (Table 2 ). These positive effects were reported both after shortterm (3 months) and longer-term follow-up (12 months). The weighted mean PCS was 33.2 preoperatively and increased significantly to 45.3 postoperatively (weighted mean increase of 35.5%). The MCS increased from 44.6 preoperatively to 50.9 postoperatively (þ13.7%). PAS scores improved from 561.5 preoperatively to 302.3 postoperatively [À259 points (À46.2%)]. Yang In the study by Yang et al. [27] , the MCS slightly decreased 1 month postoperatively compared with preoperatively.
Effect of cinacalcet on QoL
Filipozzi et al. [31] (n ¼ 124) reported absolute values. At baseline, PCS and MCS scores were 38.6 6 5.3 and 45.5 6 7.4, respectively. At the end of follow-up, the PCS score was 38.7 6 5.3 and the MCS score was 44.6 6 7.7. No P-values were Results are reported as mean 6 SD or median (25th-75th percentile).
P T x a n d c i n a c a l c e t i n E S R D -r e l a t e d H P T provided. Briggs et al. [30] (n ¼ 1780) reported QoL data expressed as EQ-5D scores. The estimated treatment effect of cinacalcet at the end of follow-up did not reach statistical significance compared with placebo. Chertow et al. [29] analysed 567 patients who participated in an open-label clinical trial that showed that cinacalcet had a significant positive effect on 4 of 14 related symptoms at the end of the study (dry skin, ache in bones, joint pain and trouble with memory). However, no significant changes were seen in PCS and MCS scores both at the end of the efficacy assessment (16-22 weeks) and at end of follow-up (12 months).
D I S C U S S I O N
This is the first systematic review to examine the impact of PTx and cinacalcet on QoL in the treatment of HPT. In all, eight peer-reviewed studies published between 2000 and 2015 were analysed. Patients with secondary and tertiary HPT who underwent PTx experienced a significant improvement in QoL. Cinacalcet, on the other hand, did not convincingly have a positive effect on QoL.
HPT develops in 30-50% of all patients with ESRD [2] . It is well recognized that ESRD and accompanying complications are associated with polypharmacy, a decreased life expectancy and a reduced QoL [33] . Strikingly, only a few studies assessed the effect of PTx and cinacalcet on QoL as an endpoint in the fragile ESRD population. In this review, we summarized available data related to the impact of PTx and cinacalcet on QoL in ESRD patients with HPT. Our data suggest that PTx might improve QoL in these patients, whereas cinacalcet does not seem to influence QoL.
The improvement of QoL after PTx is probably caused by the resection of almost all parathyroid tissue, resulting in a strong correction of PTH overproduction. Due to the extremely short half-life of PTH (<2 min), serum PTH drops immediately, leading to low serum PTH levels [34] . Thus HPT-related symptoms as described by Pasieka et al. [4] , such as bone pain, fatigue and depression, diminish almost immediately after PTx. It should be noted that none of the included articles on the effect of PTx were sham controlled. It is likely that bias introduced by the lack of sham controlled surgery plays a substantial role in the improvement patients experienced after PTx. Thus, although the individual studies in our meta-analysis were considered to be of reasonable to good quality, the level of evidence to support the effect of PTx on QoL remains low. On the other hand, patients require fewer medications after surgery, which also benefits QoL.
Several studies have investigated the influence of cinacalcet on QoL in the ESRD patient population [29] [30] [31] 35] . These studies showed less promising results when compared with the QoL improvement after PTx. Our findings are in line with data by Cunningham et al. [35] , who undertook a compared analysis of four unpublished RCTs of QoL in patients with HPT treated with either cinacalcet (n ¼ 665) or placebo (n ¼ 471). The main outcome was that only two (bodily pain and general health) of the eight domains of the SF-36 improved significantly in the cinacalcet group, compared with the control group with a difference of <2 points, while a difference of 3-5 points is considered clinically meaningful [23, 35] . The fact that cinacalcet does not seem effective in improving QoL may be explained, at least partly by the occurrence of side effects, such as nausea, vomiting and diarrhoea, which may counteract potential QoL improvements due to PTH lowering [32] . We found no study directly comparing the effects of cinacalcet with PTx on QoL.
The strength of this systematic review is our methodological approach. After establishing a well-designed reproducible search string in collaboration with an experienced medical librarian, the selection and analysis were conducted by three individual reviewers. Afterwards, selected manuscripts were assessed on their quality using validated quality assessment tools, also independently by three authors. This assessment indicates that all studies were of enough quality to address our question. Limitations of this review are inherent to the study population. QoL is influenced by many factors and it remains difficult to assess the true benefit of surgery alone in the absence of sham controls. In addition, data are limited and, unfortunately, no meta-analysis was possible. Due to the lack of data, we could not test the risk for publication bias. However, we do acknowledge the potential risk for publication bias, which should be taken into account when interpreting the results. Lastly, the search protocol has not been published or presented to an ethical committee.
With the availability of calcimimetics, PTx is now only indicated in patients with uncontrollable HPT [10] . However, in the last decade the quality of parathyroid surgery has improved with the use of less invasive surgical methods, heat-sealing devices and improved imaging for preoperative localization [36, 37] . This notwithstanding, PTx remains a surgical procedure executed in a fragile population with cause-specific morbidity, including hypocalcaemia and emergency admissions (myocardial dysrhythmias, cerebrovascular events) as described in a large US nationwide study [38] . These data might explain the hesitance of nephrologists to refer their patients for surgery and their increased motivation for treatment with cinacalcet [39] . The intravenous calcimimetic etelcalcetide was recently approved by the EMA and will become available on the European market in 2017, which may provide a further impetus for upfront medical management of HPT [40] . On the other hand, we demonstrated that PTx is a safe procedure with low complication rates when performed in a tertiary referral centre. Post-operative complications, including surgical site problems (3.5%), temporary recurrent laryngeal nerve damage (1.8%) and intensive care admissions (0.8%) were rare. Postoperative hypocalcaemia was seen in 39.8% of patients [13] . This difference might indicate the necessity of referring these fragile patients to high-volume centres. Despite data indicating that surgical intervention is highly effective, has a positive effect on QoL and is safe when performed in an experienced centre, pharmacological treatment has so far remained the first-line treatment for advanced HPT [13, 14, 41] . In order to ultimately compare the short-term and long-term effects of cinacalcet and PTx on QoL in HPT patients, an RCT will soon be conducted (EudraCT no. 2016-002174-12). Along with results comparing biochemical effects and cost-effectiveness, recommendations for renewed guidelines should be established.
PTx improved QoL in patients treated for ESRD-related HPT, whereas cinacalcet did not. In order to provide a patienttailored approach for the treatment of HPT, biochemical, clinical and QoL changes must be taken into account.
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R E F E R E N C E S A B S T R A C T
Background. Racial differences in overall mortality rates have been found in children on renal replacement therapy (RRT). We used data from the European Society for Paediatric Nephrology/ European Renal Association -European Dialysis and Transplant Association Registry to study racial variation in the prevalence of cardiovascular disease (CVD) risk factors among European children on RRT. Methods. We included patients aged <20 years between 2006-13 who (i) initiated dialysis treatment or (ii) had a renal transplant vintage of !1 year. Racial groups were defined as white, black, Asian and other. The CVD risk factors assessed included uncontrolled hypertension, obesity, hyperphosphataemia and anaemia. Differences between racial groups in CVD risk factors were examined using generalized estimating equation (GEE) models while adjusting for potential confounders. Results. In this study, 1161 patients on dialysis and 1663 patients with a transplant were included. The majority of patients in both groups were white (73.8% and 79.9%, respectively). The crude prevalence of the CVD risk factors was similar across racial groups. However, after adjustment for potential confounders, Asian background was associated with higher risk of uncontrolled hypertension both in the dialysis group [odds ratio (OR): 1. 
